Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pasteur MSD gets Zostavax through first EU-wide rapid assessment

This article was originally published in Scrip

Executive Summary

Sanofi Pasteur MSD (SPMSD) is the first pharmaceutical company to go through a pilot scheme run by the European network of health technology assessment agencies (EUnetHTA), which is aimed at rapidly producing relative effectiveness assessments to be used by HTAs across Europe. The company's shingles vaccine Zostavax was declared more effective than placebo. The challenge now is to persuade a knot of resistant European countries to use EUnetHTA's report in their national reimbursement assessments, rather than duplicating the same sorts of studies at regional level. EUnetHTA must also convince companies that the benefits of the scheme outweigh the risks associated with a potentially negative pan-European outcome.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC023183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel